Recro Pharma Inc. (REPH) Shares Up 7.1%
Recro Pharma Inc. (NASDAQ:REPH) shares shot up 7.1% during trading on Monday . The company traded as high as $10.85 and last traded at $9.80, with a volume of 149,949 shares changing hands. The stock had previously closed at $9.15.
A number of research firms recently commented on REPH. Janney Montgomery Scott began coverage on Recro Pharma in a report on Monday. They issued a “buy” rating and a $21.00 price objective on the stock. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. Brean Capital reiterated a “buy” rating and issued a $28.00 price objective on shares of Recro Pharma in a research note on Thursday, August 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of Recro Pharma in a research note on Monday, July 18th.
The stock’s market cap is $89.91 million. The stock has a 50-day moving average of $8.83 and a 200 day moving average of $7.54.
Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings data on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.05. The company had revenue of $17.30 million for the quarter, compared to analyst estimates of $18.70 million. On average, equities research analysts forecast that Recro Pharma Inc. will post ($3.23) EPS for the current year.
In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin acquired 390,000 shares of the stock in a transaction that occurred on Tuesday, August 16th. The stock was acquired at an average price of $7.50 per share, with a total value of $2,925,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.